The effects of chemical porphyrogens and drugs on the activity of rat liver tryptophan pyrrolase.
1. Drugs such as phenobarbitone and phenylbutazone, which increase the concentration of microsomal haem and cytochrome P-450, also increase the saturation of rat liver apo-(tryptophan pyrrolase) with its haem activator, as does the haem precursor 5-aminolaevulinate. 2. At 4h after the administration of the porphyrogens 2-allyl-2-isopropylacetamide, 3,5-diethoxycarbonyl-1,4-dihydrocollidine and griseofulvin, the total pyrrolase activity is increased whereas the haem saturation of the apoenzyme is decreased. This decreased saturation is prevented by pretreatment of the animals with the inhibitor of drug-metabolizing enzymes, SKF 525-A. 3. Pretreatment of rats with the above porphyrogens inhibits the rise in holo-(tryptophan pyrrolase) activity produced by subsequent administration of cortisol, tryptophan and 5-aminolaevulinate with two single exceptions, the possible reasons for which are discussed. 4. At 24h after the administration, in starved rats, of a single daily injection of the above porphyrogens for 1 or 2 days, the holoenzyme activity is significantly increased. 5. It is suggested that the saturation of rat liver apo-(tryptophan pyrrolase) with its haem activator can be modified by treatment known to cause destruction, inhibition of synthesis, increased utilization and enhanced synthesis of liver haem. The possible involvement of the latter phenomenon in the aetiology of mental disorders in some patients with porphyria is discussed.
D000081:Acetamides / Q000494:pharmacology*; D000502:Allylisopropylacetamide / Q000494:pharmacology; D000818:Animals; D001059:Apoproteins; D003577:Cytochrome P-450 Enzyme System; D003998:Dicarboxylic Acids / Q000494:pharmacology; D006118:Griseofulvin / Q000494:pharmacology*; D006418:Heme; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007982:Levulinic Acids / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D001523:Mental Disorders / Q000209:etiology; D008861:Microsomes; D010634:Phenobarbital / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology; D011164:Porphyrias / Q000150:complications; D011335:Proadifen / Q000494:pharmacology; D011498:Protein Precursors; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D013217:Starvation; D013997:Time Factors; D014364:Tryptophan / Q000494:pharmacology; D014366:Tryptophan Oxygenase / Q000378:metabolism*
D000081:Acetamides; D001059:Apoproteins; D003998:Dicarboxylic Acids; D007982:Levulinic Acids; D011498:Protein Precursors; D011725:Pyridines; D000502:Allylisopropylacetamide; D006118:Griseofulvin; D006418:Heme; D014364:Tryptophan; D003577:Cytochrome P-450 Enzyme System; D011335:Proadifen; D014366:Tryptophan Oxygenase; D010653:Phenylbutazone; D006854:Hydrocortisone; D010634:Phenobarbital